A Case of Myxedema Coma and Adrenal Insufficiency Post Pembrolizumab.

IF 0.9 Q4 ENDOCRINOLOGY & METABOLISM Case Reports in Endocrinology Pub Date : 2024-07-10 eCollection Date: 2024-01-01 DOI:10.1155/2024/5444975
Andrew El Alam, Mohamad Fleifel, Dana El Masri, Bertha Maria Nassani, Jessica Abou Chaaya, Mahamadou Minkailou, Mariana Barbat, Arnaud Monier
{"title":"A Case of Myxedema Coma and Adrenal Insufficiency Post Pembrolizumab.","authors":"Andrew El Alam, Mohamad Fleifel, Dana El Masri, Bertha Maria Nassani, Jessica Abou Chaaya, Mahamadou Minkailou, Mariana Barbat, Arnaud Monier","doi":"10.1155/2024/5444975","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite their important clinical benefits, immune checkpoint inhibitors (ICIs) are associated with a spectrum of side effects known as immune-related adverse events (irAEs). These can be of various organ system backgrounds, including dermatologic, pulmonary, gastrointestinal, and endocrine. Polyglandular endocrinopathies (PLEs) post-ICIs therapy has been reported in the literature; however, to our knowledge, only a few have been documented with pembrolizumab. <i>Case Report</i>. We present a case of a female patient who developed myxedema coma (MC) and adrenal insufficiency (AI) after 4 months of stopping pembrolizumab, a programed-cell death-1 inhibitor. The patient was clinically symptomatic and was subsequently treated with levothyroxine and hydrocortisone. <i>Discussion</i>. It is very important to be vigilant and alert in detecting MC and AI to avoid any mortality. Pembrolizumab's effect on inducing antitumor responses leads to a wide variety of multiorgan alterations. Its role in raising the risk of all-grade endocrine disorders has been previously highlighted along with thyroidal dysfunctions. Our patient's presentation falls within the literature-based median time for hypothyroidism and AI with respect to the period from the initiation of pembrolizumab. The patient's predisposition to hypothyroidism and the likelihood of intertwined manifestations of AI and hypothyroidism should always be considered in the setting of critical illness.</p><p><strong>Conclusion: </strong>It is of high significance to explore the mechanism of action of ICIs and their side effects. PLEs can house some endocrinologic emergencies that are life threatening.</p>","PeriodicalId":9621,"journal":{"name":"Case Reports in Endocrinology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254456/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/5444975","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite their important clinical benefits, immune checkpoint inhibitors (ICIs) are associated with a spectrum of side effects known as immune-related adverse events (irAEs). These can be of various organ system backgrounds, including dermatologic, pulmonary, gastrointestinal, and endocrine. Polyglandular endocrinopathies (PLEs) post-ICIs therapy has been reported in the literature; however, to our knowledge, only a few have been documented with pembrolizumab. Case Report. We present a case of a female patient who developed myxedema coma (MC) and adrenal insufficiency (AI) after 4 months of stopping pembrolizumab, a programed-cell death-1 inhibitor. The patient was clinically symptomatic and was subsequently treated with levothyroxine and hydrocortisone. Discussion. It is very important to be vigilant and alert in detecting MC and AI to avoid any mortality. Pembrolizumab's effect on inducing antitumor responses leads to a wide variety of multiorgan alterations. Its role in raising the risk of all-grade endocrine disorders has been previously highlighted along with thyroidal dysfunctions. Our patient's presentation falls within the literature-based median time for hypothyroidism and AI with respect to the period from the initiation of pembrolizumab. The patient's predisposition to hypothyroidism and the likelihood of intertwined manifestations of AI and hypothyroidism should always be considered in the setting of critical illness.

Conclusion: It is of high significance to explore the mechanism of action of ICIs and their side effects. PLEs can house some endocrinologic emergencies that are life threatening.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一例使用 Pembrolizumab 后出现肌水肿昏迷和肾上腺功能不全的病例。
背景:尽管免疫检查点抑制剂(ICIs)具有重要的临床疗效,但也会产生一系列副作用,即免疫相关不良事件(irAEs)。这些副作用可能来自不同的器官系统,包括皮肤、肺部、胃肠道和内分泌系统。有文献报道了ICIs治疗后的多腺体内分泌病(PLEs);然而,据我们所知,只有少数病例记录了使用pembrolizumab治疗后的多腺体内分泌病。病例报告。我们报告了一例女性患者在停用程序性细胞死亡-1抑制剂pembrolizumab 4个月后出现肌水肿昏迷(MC)和肾上腺功能不全(AI)的病例。患者临床症状明显,随后接受了左甲状腺素和氢化可的松治疗。讨论。在发现 MC 和 AI 时保持警惕和警觉以避免任何死亡是非常重要的。Pembrolizumab 诱导抗肿瘤反应的作用会导致多种多器官改变。以前曾强调过它与甲状腺功能障碍一样,会增加所有级别内分泌失调的风险。我们这位患者的病例与文献报道的甲状腺功能减退症和 AI 的中位时间相符,与开始使用 pembrolizumab 的时间相符。在病情危重的情况下,应始终考虑患者的甲状腺功能减退症易感性以及甲状腺功能减退症和甲状腺功能减退症交织表现的可能性:探索ICIs的作用机制及其副作用具有重要意义。PLE可引发一些危及生命的内分泌急症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Case Reports in Endocrinology
Case Reports in Endocrinology ENDOCRINOLOGY & METABOLISM-
CiteScore
2.10
自引率
0.00%
发文量
45
审稿时长
13 weeks
期刊最新文献
The Co-Occurrence of Medullary and Papillary Thyroid Carcinoma-A Literature Review Based on a Case Report. Myxedema Coma as a Presentation of Panhypopituitarism Secondary to Traumatic Brain Injury. A Single Pelvic Fibrous Tumor Associated With Doege-Potter Syndrome: A Case Study. Frequent Seronegative Primary Hypothyroidism in Myxedema Coma in Japan: Three Case Reports With a Systematic Review. A Case of Acute Hypertriglyceridemia-Induced Pancreatitis in Pregnancy and Its Clinical Implications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1